Endovia Health Sciences, Inc. (EDVA)
NYSEAMERICAN: EDVA · Real-Time Price · USD
0.1470
+0.0069 (4.93%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Endovia Health Sciences Revenue
Endovia Health Sciences had revenue of $-2.51M in the twelve months ending June 30, 2026. In the year 2025, Endovia Health Sciences had annual revenue of $73.07K, down -90.88%. That makes Endovia Health Sciences the 46,787th largest company in the world by revenue and 7,033rd in the United States.
Revenue (ttm)
$-2.51M
Revenue Growth
-90.88%
P/S Ratio
29.37
Revenue / Employee
$16,045
Employees
2
Market Cap
942.64K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.07K | -728.21K | -90.88% |
| Dec 31, 2024 | 801.27K | -18.05M | -95.75% |
| Dec 31, 2023 | 18.85M | 762.67K | 4.22% |
| Dec 31, 2022 | 18.09M | 6.77M | 59.84% |
| Dec 31, 2021 | 11.32M | 9.02M | 391.97% |
| Dec 31, 2020 | 2.30M | 2.28M | 11,182.32% |
| Dec 31, 2019 | 20.39K | -1.29M | -98.44% |
| Dec 31, 2018 | 1.31M | 413.83K | 46.22% |
| Dec 31, 2017 | 895.35K | -116.95K | -11.55% |
| Dec 31, 2016 | 1.01M | 114.95K | 12.81% |
| Dec 31, 2015 | 897.34K | 291.44K | 48.10% |
| Dec 31, 2014 | 605.91K | 130.65K | 27.49% |
| Dec 31, 2013 | 475.25K | 166.52K | 53.94% |
| Dec 31, 2012 | 308.73K | 24.90K | 8.77% |
| Dec 31, 2011 | 283.83K | -48.61K | -14.62% |
| Dec 31, 2010 | 332.43K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| Scinai Immunotherapeutics | 1.49M |
| SciSparc | 679.00K |
| BioRestorative Therapies | 357.87K |
| Decoy Therapeutics | 227.63K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
EDVA News
- 7 days ago - Endovia Health Sciences Proxy statement: Proxy filing - Filings
- 10 days ago - Endovia Health Sciences announces FDA minor-use determination for CannEpil - TheFly
- 10 days ago - Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway - GlobeNewsWire
- 10 days ago - Endovia Health Sciences Proxy statement: Proxy filing - Filings
- 22 days ago - Endovia Health Sciences Proxy statement: Proxy filing - Filings
- 23 days ago - Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways - GlobeNewsWire
- 27 days ago - Endovia Health Sciences Proxy statement: Proxy filing - Filings
- 6 weeks ago - Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline - GlobeNewsWire